The demand for patient cures is great. Unfortunately, the cost of bringing a new drug to the clinic is staggering (approximately $1B) and the time required to obtain FDA approval is prohibitively long (approximately 10 years). According to the accounting firm Deloitte, in 2019 the pharmaceutical industry will suffer a 92% failure rate and waste over $100B in R&D spending. This leads to the incalculable toll on human lives.
Consequently, there is considerable interest in improving strategies that expedite research and predict the safety and efficacy of new drugs, devices, and protocols.
Surrogen is doing its part by providing better research models that replicate human diseases in pigs, animals that are more similar to humans by nearly every measure over commonly-used mice. Surrogen’s expertise in molecular and cellular biology, genomics, embryology, animal husbandry, and production enable disease researchers the ability to answer questions about a disease or therapeutics that other models cannot.
Surrogen pigs enable a more thorough examination of the onset and progression of a human disease, and the safety and efficacy of therapeutics designed to arrest it.
When compared to traditional animal disease models, Surrogen’s gene edited pigs offer better quality data, improved decision making, decreased product development time, and ultimately a lower R&D costs to the drug and device industries. In addition, Surrogen’s gene-edited models have the ability to show comorbidity environments that more closely resemble real-world disease states.
Surrogen is developing humanized swine models of these categories of diseases:
Surrogen’s gene-edited pigs provide an unrivaled advantaged over traditional animal models. Pigs are and/or have:
Surrogen could help your preclinical R&D program to give it:
Scientists have identified more than 10,000 single gene mutations that play roles in diseases and medical conditions. Surrogen leverages its world-leading expertise in the use of gene-editing tools like transcription activator-like effector nucleases (TALENs), clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) and others to design optimized swine models for a wide array of disease-causing mutations identical to those in human patients. Thus, we are creating disease models in swine that are genetically identical and highly similar to humans.
Our science is validated in the following peer-reviewed published papers:
Engineered swine models of cancer
Published in the Frontiers in Genetics
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
Published in Nature’s Communication Biology
A new tool for mapping breast cancer risk in the tumor microenvironment
Published in Cancer Research
Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model
Published in Translational Research
In vivo genome editing using a high-efficiency TALEN system
Published in Nature
Precision editing of large animal genomes
Published in Advances in Genetics
Efficient TALEN-mediated gene knockout in livestock
Published in Proceedings of the National Academy of Sciences
Precise genome editing of PDX1 by direct injection of transcription activator-like effector nucleases (TALENS) into Parthenogenetic Pig Embryos
Published in Reproduction, Fertility and Development
Efficient Nonmeiotic Allele Introgression in Livestock Using Custom Endonucleases
Published in Proceedings of National of the National Academy of Sciences
Editing Livestock Genomes with Site-Specific Nucleases
Published in the Journal of Reproduction, Fertility and Development
Live pigs produced from genome edited zygotes
Published in Scientific Reports
TALEN-mediated gene targeting in porcine spermatogonia
Published in Molecular Reproduction and Development
Simple and efficient methods for enrichment and isolation of endonuclease modified cells
Published in PLOS One
To learn more about Surrogen, call 612-727-2000 or email email@example.com.